Dopamine is an important modulator of blood pressure, in part, by regulating vascular resistance. To test the hypothesis that D(1) and D(3) receptors interact in vascular smooth muscle cells, we studied A10 cells, a rat aortic smooth muscle cell line, and rat mesenteric arteries that express both dopamine receptor subtypes. Fenoldopam, a D(1)-like receptor agonist, increased both D(1) and D(3) receptor protein in a time-dependent and a concentration-dependent manner in A10 cells. The effect of fenoldopam was specific because a D(1)-like receptor antagonist, SCH23390 (10(-7) M/24 h), completely blocked the stimulatory effect of fenoldopam (10(-7) M/24 h) (D(3) receptor: control=21+/-1 density units [DU]); SCH23390=23+/-2 DU; fenoldopam=33+/-2 DU; fenoldopam+SCH23390=23+/-2 DU; n=10). D(1) and D(3) receptors physically interacted with each other because fenoldopam (10(-7) M/24 h) increased D(1)/D(3) receptor coimmunoprecipitation (35+/-5 versus 65+/-5 DU; n=8). A D(3) receptor agonist, PD128907, relaxed mesenteric arterial rings independent of the endothelium, effects that were blocked by a D(3) receptor antagonist, U99194A. Costimulation of D(1) and D(3) receptors led to additive vasorelaxation. We conclude that the D(1) receptor regulates the D(3) receptor by physical interaction and receptor expression. D(1) receptor stimulation augments D(3) receptor vasorelaxant effects. An interaction of D(1) and D(3) receptors may be involved in the regulation of blood pressure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/01.HYP.0000118958.27649.6f | DOI Listing |
Eur J Med Chem
January 2025
School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China. Electronic address:
Temozolomide, a widely used alkylating agent for glioblastoma treatment, faces significant challenges due to the development of resistance, which severely impacts patient survival. This underscores the urgent need for novel strategies to overcome this barrier. Focal adhesion kinase (FAK), an intracellular non-receptor tyrosine kinase, is highly expressed in glioblastoma cells and has been identified as a promising therapeutic target for anti-glioblastoma drug development.
View Article and Find Full Text PDFRev Neurosci
January 2025
School of Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China.
Cholecystokinin (CCK) is a major neuropeptide in the brain that functions as a neurotransmitter, hormone, and growth factor. The peptide and its receptors are widely expressed in the brain. CCK signaling modulates synaptic plasticity and can improve or impair memory formation, depending on the brain areas studies and the receptor subtype activated.
View Article and Find Full Text PDFChem Biodivers
January 2025
UNIFESSPA: Universidade Federal do Sul e Sudeste do Para, Faculdade de Psicologia, Rod. BR-230 (Transamazônica), Loteamento Cidade Jardim, Av. dos Ipês, s/n.º - Ci, 68503000, Marabá, BRAZIL.
Chrysin (5,7-dihydroxyflavone) is a natural flavonoid with potential anxiolytic-like effects in preclinical models. Acute treatment with this molecule (0 - 10 mg/kg) produced a biphasic dose-response in the zebrafish light/dark test (LDT), with anxiolytic-like effect at low doses and anxiogenic-like effects at high doses. Chrysin (1 mg/kg) decreased anxiety-like behavior in the zebrafish novel tank test (NTT), but did not prevent the anxiogenic effects of acute stress.
View Article and Find Full Text PDFJ Pharm Pharmacol
January 2025
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, 333031, Rajasthan, India.
Objectives: Chronic kidney disease (CKD) is a serious health issue with rising morbidity and mortality rates. Despite advances in understanding its pathophysiology, effective therapeutic options are limited, necessitating innovative treatment approaches. Also, current frontline treatments that are available against CKD are not uniformly effective and often come with significant side effects.
View Article and Find Full Text PDFAm J Physiol Heart Circ Physiol
January 2025
Cardiovascular Translational Research. Navarrabiomed (Fundación Miguel Servet), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Diabetes mellitus (DM) increases the risk of aortic stenosis (AS) and worsens its pathophysiology in a sex-specific manner. Aldosterone/mineralocorticoid receptor (Aldo/MR) pathway participates in early stages of AS and in other diabetic-related cardiovascular complications. We aim to identify new sex-specific Aldo/MR targets in AS complicated with DM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!